Acasti Pharma is a biopharmaceutical company that is focused on developing and commercializing products for rare and orphan diseases by using its drug delivery technologies. Co.'s primary drug candidate, GTX-104, is an IV formulation of nimodipine designed to treat subarachnoid hemorrhage, a rare brain disorder. Co.'s other drug candidates are: GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia, an orphan pediatric genetic neurodegenerative disorder in young children; and GTX-101, which is a topical bioadhesive film-forming bupivacaine spray for Postherpetic Neuralgia, which causes debilitating pain following infection by the shingles virus. The ACST YTD return is shown above.
The YTD Return on the ACST YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACST YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACST YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|